Jin Rui, Huang Jian-Mei, Wang Yu-Guang, Zhang Bing
Department of Pharmacy, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.
Research Center for Chinese Medicine Pharmacovigilance and Rational Drug Use, Beijing University of Chinese Medicine, Beijing 100029, China.
Zhongguo Zhong Yao Za Zhi. 2016 Feb;41(3):545-549. doi: 10.4268/cjcmm20160332.
Combined use of Chinese medicine and western medicine is one of the hot spots in the domestic medical and academic fields for many years. There are lots of involved reports and studies on interaction problems due to combined used of Chinese medicine and western medicine, however, framework understanding is still rarely seen, affecting the clinical rationality of drug combinations. Actually, the inference ideas of drug interactions in clinical practice are more extensive and practical, and the overall viewpoint and pragmatic idea are the important factors in evaluating the rationality of clinical drug combinations. Based on above points, this paper systemically analyzed the existing information and examples, deeply discuss the embryology background (environment and action mechanism of interactions), and principally divided the interactions into three important and independent categories. Among the three categories, the first category (Ⅰapproach) was defined as the physical/chemical reactions after direct contact in vivo or in vitro, such as the combination of Chinese medicine injections and western medicine injections (in vitro), combination of bromide and Chinese medicines containing cinnabar (in vivo). The evaluation method for such interactions may be generalized theory of Acid-Base reaction. The second category (Ⅱ approach) was defined as the interactions through the pharmacokinetic process including absorption (such as the combination of aspirin and Huowei capsule), distribution (such as the combination of artosin and medicinal herbs containing coumarin), metabolism (such as the combination of phenobarbital and glycyrrhiza) and excretion (such as the combination of furadantin and Crataegi Fructus). The existing pharmacokinetic theory can act as the evaluation method for this type of interaction. The third category (Ⅲ approach) was defined as the synergy/antagonism interactions by pharmacological effects or biological pathways. The combination of warfarin and Salvia miltiorrhiza is an example for synergy interaction, while the combination of guanethidine and ephedra is an example for anatagonism interaction. The repeated application of Chinese and western medicine compound preparations and same type of western medicine also belongs to this approach. The receptor competition theory under the view of the overall pathways might act as the evaluation method for this type of interactions. Above all, the research framework on interactions between Chinese medicine and western medicine was proposed, providing overall thinking and support for the essential study on combined application of Chinese medicine and western medicine.
中西医结合是多年来国内医学和学术领域的热点之一。关于中西医联合应用的相互作用问题,有大量相关报道和研究,但系统性的认识框架仍较为少见,影响了临床用药组合的合理性。实际上,临床实践中药物相互作用的推理思路更为广泛和实用,整体观和务实理念是评估临床药物组合合理性的重要因素。基于上述观点,本文系统分析了现有资料和实例,深入探讨了相互作用的发生背景(环境及作用机制),并将相互作用主要分为三个重要且独立的类别。在这三个类别中,第一类(Ⅰ类途径)被定义为体内或体外直接接触后的物理/化学反应,如中药注射剂与西药注射剂的配伍(体外)、溴化物与含朱砂的中药的配伍(体内)。此类相互作用的评价方法可概括为酸碱反应理论。第二类(Ⅱ类途径)被定义为通过包括吸收(如阿司匹林与藿香胶囊的配伍)、分布(如阿托西汀与含香豆素的草药的配伍)、代谢(如苯巴比妥与甘草的配伍)和排泄(如呋喃妥因与山楂的配伍)等药代动力学过程产生的相互作用。现有的药代动力学理论可作为此类相互作用的评价方法。第三类(Ⅲ类途径)被定义为通过药理作用或生物学途径产生的协同/拮抗相互作用。华法林与丹参的配伍是协同相互作用的一个例子,而胍乙啶与麻黄的配伍是拮抗相互作用的一个例子。中西药复方制剂及同类西药的重复应用也属于此类途径。整体途径视角下的受体竞争理论可作为此类相互作用的评价方法。综上所述,提出了中西医相互作用的研究框架,为中西医联合应用的本质研究提供了整体思路和支持。